Placebo + Orforglipron for hypertension

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Apr 2025: Trial registered, NCT06948422
  2. 30 Apr 2025: Trial started, NCT06948422

The trials

NCT06948422: A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

State
Under way
Phase
Phase 3
People
974 planned
Started
30 Apr 2025
Primary completion
Sep 2027
Arms
Orforglipron (GZL1), Orforglipron (GZL2)
Results
None posted
  1. 29 Apr 2025: Trial registered
  2. 30 Apr 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.